A quick peek into the report
Table of Contents
1.1 Industry Outlook
1.1.1 Introduction
1.1.2 Market Overview and Ecosystem
1.1.3 Epidemiological Analysis of Human Immunodeficiency Virus Type-1
1.1.3.1 U.S.
1.1.3.2 EU5
1.1.3.3 Rest-of-the-World
1.1.4 Market Trends
1.1.5 Clinical Trials
1.1.5.1 By Phase
1.1.6 Regulatory Landscape / Compliances
1.1.6.1 Legal Requirement and Framework in U.S.
1.1.6.2 Legal Requirement and Framework in E.U.
1.1.6.3 Legal Requirement and Framework in Asia-Pacific
1.1.6.3.1 Japan
1.1.6.3.2 China
1.1.6.3.3 India
1.1.6.4 Legal Requirement and Framework in Rest-of-the-World
1.1.7 Pricing Analysis
1.2 Market Dynamics
1.2.1 Market Drivers
1.2.1.1 Impact Analysis
1.2.2 Market Restraints
1.2.2.1 Impact Analysis
1.2.3 Market Opportunities
2.1 Overview
2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
2.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
2.4 Protease Inhibitors (PIs)
2.5 Fusion Inhibitors
2.6 Integrase Strand Transfer Inhibitor (INSTIs)
2.7 Others (Capsid Inhibitors, Attachment Inhibitors, and Post-Attachment Inhibitors, among others)
3.1 North America
3.1.1 Market Dynamics
3.1.1.1 Impact Analysis
3.1.2 North America Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.1.3 North America Human Immunodeficiency Virus Type-1 Market (by Country)
3.1.4 U.S.
3.1.4.1 Market Dynamics
3.1.4.2 Market Size and Forecast
3.1.4.2.1 U.S. Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.1.5 Canada
3.1.5.1 Market Dynamics
3.1.5.2 Market Size and Forecast
3.1.5.2.1 Canada Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2 Europe
3.2.1 Market Dynamics
3.2.1.1 Impact Analysis
3.2.2 Europe Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.3 Europe Human Immunodeficiency Virus Type-1 Market (by Country)
3.2.4 U.K.
3.2.4.1 Market Dynamics
3.2.4.2 Market Size and Forecast
3.2.4.2.1 U.K. Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.5 Germany
3.2.5.1 Market Dynamics
3.2.5.2 Market Size and Forecast
3.2.5.2.1 Germany Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.6 France
3.2.6.1 Market Dynamics
3.2.6.2 Market Size and Forecast
3.2.6.2.1 France Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.7 Italy
3.2.7.1 Market Dynamics
3.2.7.2 Market Size and Forecast
3.2.7.2.1 Italy Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.8 Spain
3.2.8.1 Market Dynamics
3.2.8.2 Market Size and Forecast
3.2.8.2.1 Spain Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.2.9 Rest-of-Europe
3.2.9.1 Market Dynamics
3.2.9.2 Market Size and Forecast
3.2.9.2.1 Rest-of-Europe Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3 Asia-Pacific
3.3.1 Market Dynamics
3.3.1.1 Impact Analysis
3.3.2 Asia-Pacific Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.3 Asia-Pacific Human Immunodeficiency Virus Type-1 Market (by Country)
3.3.4 Japan
3.3.4.1 Market Dynamics
3.3.4.2 Market Size and Forecast
3.3.4.2.1 Japan Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.5 China
3.3.5.1 Market Dynamics
3.3.5.2 Market Size and Forecast
3.3.5.2.1 China Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.6 India
3.3.6.1 Market Dynamics
3.3.6.2 Market Size and Forecast
3.3.6.2.1 India Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.7 Australia
3.3.7.1 Market Dynamics
3.3.7.2 Market Size and Forecast
3.3.7.2.1 Australia Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.8 South Korea
3.3.8.1 Market Dynamics
3.3.8.2 Market Size and Forecast
3.3.8.2.1 South Korea Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.3.9 Rest-of-Asia-Pacific
3.3.9.1 Market Dynamics
3.3.9.2 Market Size and Forecast
3.3.9.2.1 Rest-of-Asia-Pacific Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.4 Latin America
3.4.1 Market Dynamics
3.4.1.1 Impact Analysis
3.4.2 Latin America Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.4.3 Latin America Human Immunodeficiency Virus Type-1 Market (by Country)
3.4.4 Brazil
3.4.4.1 Market Dynamics
3.4.4.2 Market Size and Forecast
3.4.4.2.1 Brazil Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.4.5 Mexico
3.4.5.1 Market Dynamics
3.4.5.2 Market Size and Forecast
3.4.5.2.1 Mexico Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.4.6 Rest-of-Latin America
3.4.6.1 Market Dynamics
3.4.6.2 Market Size and Forecast
3.4.6.2.1 Rest-of-Latin America Human Immunodeficiency Virus Type-1 Market (by Drug Class)
3.5 Rest-of-the-World
3.5.1 Market Dynamics
3.5.2 Market Size and Forecast
3.5.2.1 Rest-of-the-World Human Immunodeficiency Virus Type-1 Market (by Drug Class)
4.1 Competitive Benchmarking
4.2 Growth-Share Matrix (2024)
4.2.1 By Drug Class
4.3 Competitive Landscape
4.3.1 Key Strategies and Developments by Company
4.3.1.1 Funding Activities
4.3.1.2 Mergers and Acquisitions
4.3.1.3 Regulatory Approvals
4.3.1.4 Partnerships, Collaborations and Business Expansions
4.3.2 Key Developments Analysis
4.4 Company Profiles
4.4.1 Gilead Sciences, Inc.
4.4.1.1 Company Overview
4.4.1.2 Product Portfolio
4.4.1.3 Target Customers/End Users
4.4.1.4 Analyst View
4.4.2 ViiV Healthcare
4.4.2.1 Company Overview
4.4.2.2 Product Portfolio
4.4.2.3 Target Customers/End Users
4.4.2.4 Analyst View
4.4.3 Janssen Pharmaceuticals
4.4.3.1 Company Overview
4.4.3.2 Product Portfolio
4.4.3.3 Target Customers/End Users
4.4.3.4 Analyst View
4.4.4 Bristol-Myers Squibb
4.4.4.1 Company Overview
4.4.4.2 Product Portfolio
4.4.4.3 Target Customers/End Users
4.4.4.4 Analyst View
4.4.5 AbbVie Inc.
4.4.5.1 Company Overview
4.4.5.2 Product Portfolio
4.4.5.3 Target Customers/End Users
4.4.5.4 Analyst View
4.4.6 Boehringer Ingelheim
4.4.6.1 Company Overview
4.4.6.2 Product Portfolio
4.4.6.3 Target Customers/End Users
4.4.6.4 Analyst View
4.4.7 GlaxoSmithKline
4.4.7.1 Company Overview
4.4.7.2 Product Portfolio
4.4.7.3 Target Customers/End Users
4.4.7.4 Analyst View
4.4.8 Merck
4.4.8.1 Company Overview
4.4.8.2 Product Portfolio
4.4.8.3 Target Customers/End Users
4.4.8.4 Analyst View
4.4.9 Theratechnologies Inc.
4.4.9.1 Company Overview
4.4.9.2 Product Portfolio
4.4.9.3 Target Customers/End Users
4.4.9.4 Analyst View
4.4.10 Sandoz
4.4.10.1 Company Overview
4.4.10.2 Product Portfolio
4.4.10.3 Target Customers/End Users
4.4.10.4 Analyst View
Research Methodology
Table: Global Human Immunodeficiency Virus Type-1 Market, Regulatory Scenario
Table: Global Human Immunodeficiency Virus Type-1 Market Dynamics, Impact Analysis
Table: Global Human Immunodeficiency Virus Type-1 Market (by Drug Class), $Million, 2023-2035
Figure: Global Human Immunodeficiency Virus Type-1 Market, Market Overview
Figure: Global Human Immunodeficiency Virus Type-1 Market, Epidemiological Analysis, U.S.
Figure: Global Human Immunodeficiency Virus Type-1 Market, Epidemiological Analysis, EU5
Figure: Global Human Immunodeficiency Virus Type-1 Market Coverage
Figure: Global Human Immunodeficiency Virus Type-1 Market Key Trends, Impact Analysis, 2023-2035
Figure: Global Human Immunodeficiency Virus Type-1 Market, Competitive Landscape, January 2022-April 2025
Human Immunodeficiency Virus Type-1 Market Report Coverage
|
Human Immunodeficiency Virus Type-1 Market |
|||
|
Base Year |
2024 |
Market Size in 2025 |
$XX Million |
|
Forecast Period |
2025-2035 |
Value Projection and Estimation by 2035 |
$XX Million |
|
CAGR During Forecast Period |
XX% |
|
|
Key Market Players and Competition Synopsis
The companies that are profiled in the global human immunodeficiency virus type-1 market have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.
The top segment players include human immunodeficiency virus type-1 therapy providers that capture around 95% of the global human immunodeficiency virus type-1 market.
Some of the prominent names established in the global human immunodeficiency virus type-1 market are:
• Gilead Sciences, Inc.
• ViiV Healthcare
• Janssen Pharmaceuticals
• Bristol-Myers Squibb
• AbbVie Inc.
• Merck
• Boehringer Ingelheim
• GlaxoSmithKline
• Theratechnologies Inc.
• Sandoz
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Product launches and innovations in the global human immunodeficiency virus type-1 market are focused on advancing treatment options and diagnostic technologies to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of HIV-1. Key players in the market, such as Gilead Sciences and Merck & Co., have been involved in the development of novel therapies, including long-acting injectable treatments and combination regimens, which provide improved adherence and enhanced patient outcomes. Additionally, innovations in HIV-1 diagnostics and prevention strategies such as pre-exposure prophylaxis (PrEP) are helping to reduce the spread of HIV-1 and improve disease management globally.
Competitive Strategy: Enterprises led by market leaders in the global HIV-1 market are continuously updating their product portfolios with innovative, application-specific treatments to maintain competitiveness. Companies are focusing on developing long-acting treatments, combination drugs, and novel prevention strategies to address the evolving needs of HIV-1 patients. A detailed competitive benchmarking of the key players in the global HIV-1 market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, regulatory approvals, and product launches will help readers identify untapped revenue opportunities in the market.
Industry and Technology Overview
Market Lifecycle Stage
The global human immunodeficiency virus type-1 market is currently in the growth phase of its lifecycle, driven by ongoing advancements in antiretroviral therapies (ART) and increasing global access to treatment. Since the introduction of highly effective ART, the management of HIV-1 has shifted from a fatal diagnosis to a chronic manageable condition. In recent years, the global human immunodeficiency virus type-1 market has been fueled by the introduction of long-acting therapies, dual and triple combination drugs, and the focus on prevention strategies, such as pre-exposure prophylaxis (PrEP).
The rising prevalence of HIV-1, especially in sub-Saharan Africa, alongside a growing awareness of the importance of early diagnosis and treatment, has contributed to an expanding patient base. Additionally, the availability of generics in various regions has significantly reduced treatment costs, leading to broader access to ART. Despite these positive developments, the global human immunodeficiency virus type-1 market still faces challenges, such as the high cost of newer therapies and side effects of long-term ART. However, innovations in treatment adherence, new drug formulations, and vaccine research are expected to propel the global human immunodeficiency virus type-1 market further in the coming years.
The global human immunodeficiency virus type-1 market is thus positioned in a mature growth phase, with continued expansion driven by technological innovations, global access initiatives, and research into a functional cure or HIV vaccines, making it an attractive area for continued investment and innovation.
Impact
• Increasing demand for human immunodeficiency virus type-1 therapies is anticipated to support the growth of the global human immunodeficiency virus type-1 market during the forecast period 2025-2035.
• The global human immunodeficiency virus type-1 market is expected to grow at a significant rate due to the increasing prevalence of the disease, advancements in antiretroviral therapies (ART), and the growing adoption of long-acting treatments that offer more effective and convenient management of HIV. Additionally, the expanding research pipeline, including efforts to develop a functional cure and HIV vaccines, as well as the potential for pre-exposure prophylaxis (PrEP) and non-invasive treatment options, are anticipated to drive the global human immunodeficiency virus type-1 market expansion in the near future.
Market Segmentation:
Segmentation 1: by Drug Class
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
• Protease Inhibitors (PIs)
• Fusion Inhibitors
• Integrase Strand Transfer Inhibitor (INSTIs)
• Others
Segmentation 2: by Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest-of-the-World
Recent Developments in the Global Human Immunodeficiency Virus Type-1 Market
• Partnerships: In October 2024, Dr. Reddy’s Laboratories Ltd. entered into an agreement with Gilead Sciences Ireland UC for the manufacture and commercialization of the drug Lenacapavir in India and 120 other countries.
• Product Launch: In August 2023, Aurobindo Pharma Ltd announced the launch of its HIV triple combination product formulated specifically for children living with HIV in low- and middle-income countries, aiming to enhance treatment accessibility and support pediatric HIV care in resource-limited settings.
• Regulatory Approval: In December 2022, the U.S. FDA approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with human immunodeficiency virus type 1 (HIV-1). This approval targets patients whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations.
Demand – Drivers and Limitations
The following are the drivers for the global human immunodeficiency virus type-1 market:
• Rising Prevalence and Incidence of Human Immunodeficiency Virus Type-1
• Advancements in Antiretroviral Therapy
• Access to Generics and Lower Treatment Costs
The global human immunodeficiency virus type-1 market is expected to face some limitations too, due to the following challenges:
• High Costs of Advanced Treatments
• Side Effects and Long-Term Adherence
Human Immunodeficiency Virus Type-1 Market - A Global and Regional Analysis
Focus on Drug Class and Regional Analysis - Analysis and Forecast, 2025-2035
This report will be delivered in 7-10 working days.
Frequently Asked Questions
Human immunodeficiency virus type-1 (HIV-1) is a strain of the HIV virus that causes acquired immunodeficiency syndrome (AIDS), the most common and widespread form of HIV globally. HIV-1 primarily targets the immune system, specifically the CD4+ T cells, which are crucial for immune defense. The virus enters these cells, replicates, and eventually destroys them, weakening the immune system over time and making the body more susceptible to infections and certain cancers.
Existing players in the global human immunodeficiency virus type-1 market are adopting strategies that focus on innovation, global access, and patient-centric care. By developing novel therapies, forming strategic partnerships, and investing in prevention strategies and personalized treatments, these companies are positioning themselves for long-term success in this competitive market.
Any new company entering the HIV-1 market should prioritize the development of cutting-edge biologic therapies that target specific immune mechanisms and pathways, aiming to provide more effective and personalized treatments. Additionally, establishing strategic collaborations with key industry players, research institutions, and healthcare providers would be essential for accelerating innovation and expanding market reach, ensuring the company remains competitive and at the forefront of HIV-1 care.
• Extensive competitive benchmarking of the top players in the global human immunodeficiency virus type-1 market.
• Market analysis based on product portfolio, recent developments, and regional spread.
• Epidemiological analysis of human immunodeficiency virus type-1.
• Pricing analysis and drug profiles of the human immunodeficiency virus type-1 therapies.
This report should be purchased by pharmaceutical companies, biotech firms, and investors looking to understand market trends, competitive strategies, and growth opportunities in the human immunodeficiency virus type-1 market.